Clinical trial NCT02151591: New Approaches to Smoking Cessation in Heavy Drinkers
Official title: New Approaches to Smoking Cessation in Heavy Drinkers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Nicotine Dependence
Cigarette Smoking
Alcohol Consumption
Heavy Drinking
Keywords: Quit smoking
Quit drinking
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2014-05-30
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to develop and test an integrated cognitive-behavioral intervention for smoking and alcohol among heavy drinking smokers. The current pre-pilot phase will be used to refine this protocol for the subsequent randomized, controlled pilot phase. The current study phase has two parts: 1) an intake session and brief physical; 2) a 12-week treatment phase in which participants receive varenicline (Chantix) and weekly, personalized counseling.

Detailed description: The purpose of the proposed project is to develop and test a 12-week integrated cognitive-behavioral therapy (CBT) intervention for smoking and alcohol (SA) + varenicline (Chantix) among heavy drinking smokers (i.e., CBT for SA). The project involves two phases. In Phase 1, an open-label pre-pilot study of CBT for SA will be conducted with 10 heavy drinking smokers. The primary results of this phase will be used to refine the CBT for SA protocol. In Phase 2, a randomized, controlled pilot study will be conducted with 40 heavy drinking smokers comparing CBT for SA with standard smoking counseling (SC). All participants in the randomized pilot study will also receive varenicline (Chantix).

Primary and Study Completion dates were changed 6/2016 to reflect an additional year added year to the study.

Eligibility criteria: Inclusion Criteria:

1. are at least 18 years of age;
2. report smoking 100 cigarettes over lifetime and currently smoke at least twice weekly on average in the past 90 days and have a urinary cotinine level of \>=30ng/mL by semi-quantitative analysis, and/or \>= 2 on a NicAlert dipstick
3. are interested in quitting smoking;
4. understand English;
5. exceed National Institute on Alcohol Abuse and Alcoholism heavy drinking criteria (i.e., for men, \>14 drinks/week or 5 drinks/day at least once per month over the past 12 months; for women, \>7 drinks/week or \>4 drinks/day at least once per month over the past 12 months.

Exclusion Criteria:

1. meet criteria for alcohol dependence in the past 12 months that is clinically severe defined by

   * a history of seizures, delirium, or hallucinations during alcohol withdrawal;
   * a Clinical Institute Withdrawal Assessment scale (Sullivan et al., 1989) score of \> 8;
   * report drinking to avoid withdrawal symptoms, or d) have had prior treatment of withdrawal;
   * have required medical treatment of alcohol withdrawal within the past 6 months;
2. are currently enrolled in alcohol treatment;
3. meet criteria for drug dependence in the past 12 months; with the exception of marijuana dependence
4. exhibit serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder, organic mood or mental disorders by history or psychological examination;
5. report current suicidality (past 12 months), or report suicide attempts within the past 10 years, assessed with the Columbia Suicide Severity Rating Scale;
6. exhibit current, clinically significant physical disease or abnormality based on medical history, physical examination, or routine laboratory evaluation including:

   * any unexplained elevations in liver enzymes (i.e., transaminases, bilirubin);
   * clinically significant, unstable cardiovascular disease/uncontrolled hypertension;
   * hepatic or renal impairment;
   * severe obstructive pulmonary disease;
   * diabetes mellitus requiring insulin or certain oral medications (i.e., sulfonylureas) and an A1C hemoglobin test score of \> 7 for participants not prescribed these medications;
   * baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg;
7. are cognitively impaired;
8. are unable to read/understand English;
9. are a female of childbearing potential who is pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide);
10. report new onset of psychiatric disorders or new psychotropic medications within the past 3 months, except individuals who are on a stable dose of a Selective Serotonin Reuptake Inhibitor for at least two months or who report occasional use of prescription sleep aids that they are willing to discontinue;
11. have used another investigational drug within 30 days or have used medications to treat alcohol (e.g., naltrexone, topiramate, acamprosate, disulfiram) or nicotine use (e.g., clonidine, varenicline, bupropion, nicotine replacement) in the past 3 months or intend to use these medications; (prior use of nicotine replacement in situations where smoking is not permitted (e.g., planes) without the intention to quit smoking is not exclusionary at screening)
12. intend to donate blood or blood products during the treatment phase of the study;
13. have a history of cancer (except treated basal cell or squamous cell carcinoma of the skin);
14. have a history of serious hypersensitivity reactions or skin reactions to varenicline.

Primary outcomes:
measure: Number of Participants With Smoking Abstinence at 6 Months
timeFrame: 6 months post treatment start
Secondary outcomes:
measure: Log Transformed Percentage of Heavy Drinking Days
timeFrame: 6 months post treatment start
measure: Number of Participants Who Completed Treatment.
timeFrame: 12 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Lisa Fucito, PhD
role: PRINCIPAL_INVESTIGATOR
References: